Pericarditis Treatment Market By Treatment Type (Nonsteroidal Anti-Inflammatory Drugs, Colchicine, Corticosteroids, IL-1 Inhibitors, Immunosuppressive Therapies, Intravenous Immunoglobulin, Other Supportive Therapies); By Application (Acute Pericarditis, Recurrent Pericarditis, Chronic Pericarditis, Constrictive Pericarditis, Post-Pericardiotomy Syndrome); By End User (Hospitals, Specialty Cardiology Centers, Ambulatory Care Centers, Specialty Clinics, Homecare Settings); By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), Segment Revenue Estimation, Forecast, 2026–2032

Pericarditis Treatment Market: Recurrent Disease Shifts Revenue Toward Long-Duration Specialty Care

The Global Pericarditis Treatment Market was valued at USD 3.30 billion in 2025 and is projected to reach USD 5.41 billion by 2032, growing at a CAGR of 6.4%, according to Strategic Market Research.

 

The pericarditis treatment market is split between high-volume conventional medicines used for initial episodes and a smaller recurrent-disease segment that generates most branded revenue. Aspirin, nonsteroidal anti-inflammatory drugs, and colchicine remain the main therapies for early treatment, limiting pricing power and supplier differentiation across uncomplicated cases. Revenue increases when patients experience repeated recurrences, remain dependent on corticosteroids, or require long-term specialist care.

 

Public commercial data are concentrated in the United States, where recurrent pericarditis has developed into a measurable specialty-pharmaceutical market. Approximately 40,000 U.S. patients are estimated to seek or receive treatment for recurrent disease each year. Around 14,000 patients with persistent disease, multiple recurrences, or inadequate response to conventional therapy form the main target for premium treatment. Another 26,000 patients experiencing a first recurrence represent the larger expansion pool if physicians identify treatment failure earlier and payers permit escalation.

 

Specialist referral, documented inflammation, failure of lower-cost therapy, insurance authorization, and treatment persistence determine how much of this population converts into branded demand. Total acute case volume matters less commercially because most patients remain on inexpensive, established medicines for relatively short periods.

 

Conventional Treatment Controls Volume, While Recurrent Care Generates Revenue

Most prescriptions remain concentrated in mature, low-cost drugs. A 2024 real-world study involving 144 patients found that 96% achieved complete remission after treatment was aligned with clinical recommendations, while only 8% required an IL-1-blocking therapy. The same study reported that 68% of patients referred to a specialist centre needed changes to their previous treatment.

Many patients can be managed without expensive long-duration treatment, while branded use is concentrated among those who continue to relapse, cannot reduce corticosteroid use, or return repeatedly for hospital and specialist care.

Updated clinical guidance has clarified treatment escalation. Conventional anti-inflammatory medicines remain the preferred starting point, while targeted IL-1 therapy is reserved for selected patients with recurrent inflammatory disease and inadequate response to first-line treatment. Clearer guidance can reduce physician hesitation, but payer policies continue to restrict access to patients with documented need.

Commercial value is tied to recurrence frequency, duration of illness, previous treatment failure, specialist involvement, and the probability that treatment will continue for several years.

 

ARCALYST Sets the Current Commercial Benchmark

ARCALYST is the only FDA-approved therapy specifically indicated for recurrent pericarditis and reduction of recurrence risk in adults and children aged 12 years and older. Its regulatory status, established clinical evidence, specialist familiarity, and specialty-pharmacy infrastructure give Kiniksa a strong advantage over off-label therapies and pipeline competitors.

Kiniksa reported ARCALYST net product revenue of USD 677.6 million in 2025, up approximately 62% from the previous year. Revenue reached USD 214.3 million in the first quarter of 2026, an increase of 56% year over year. The company later guided for USD 930 million to USD 945 million in 2026 product revenue.

These figures include ARCALYST sales across other approved indications and should not be presented as the size of the pericarditis treatment market. Kiniksa identifies recurrent pericarditis as the product’s primary commercial indication, making the revenue trend the strongest available measure of branded adoption in this niche.

More than 4,550 physicians had prescribed ARCALYST for recurrent pericarditis by the first quarter of 2026. Average treatment duration was approaching three years. New patient starts and continued use among existing patients both support revenue growth, giving the branded segment a recurring-revenue profile that differs sharply from short-course treatment in acute disease.

Long treatment duration increases the value of each successfully onboarded patient and raises the importance of insurance renewals, refill continuity, patient-support programmes, affordability assistance, and coordination between prescribers and specialty pharmacies. Administrative failure or treatment abandonment can remove several years of potential revenue rather than a single prescription.

 

Low Penetration Leaves Room for Growth, but Access Remains Difficult

Only about 18% of Kiniksa’s estimated 14,000-patient multiple-recurrence target was actively receiving ARCALYST at the end of 2025. The remaining population represents potential growth, although not every untreated patient will convert to premium therapy.

Some patients remain controlled on lower-cost medicines. Others do not reach specialists familiar with targeted treatment. Insurers may require evidence of repeated recurrence, corticosteroid dependence, inflammatory activity, or previous treatment failure before approving coverage. High cost-sharing can also delay or prevent treatment initiation.

Kiniksa’s commercial strategy increasingly addresses these barriers. Its sales organisation focuses on high-volume cardiology accounts and recurrent-pericarditis prescribers, while patient-support services assist with insurance verification, prior authorization, affordability, and treatment continuity. The company also launched a targeted consumer-awareness campaign in 2026 to encourage patients with repeated flares to discuss treatment options with healthcare providers.

Consumer promotion indicates that patient identification remains a constraint despite rising specialist adoption. Delayed diagnosis, weak referral pathways, inconsistent treatment histories, and limited awareness outside specialist centres continue to restrict prescription conversion. Companies that shorten the path from recurrence to specialist assessment can expand the treated population without relying on higher disease incidence.

The 26,000-patient first-recurrence group represents the main earlier-line opportunity. Access to this population will depend on evidence supporting earlier use, payer acceptance, and physician confidence that escalation can reduce repeated episodes and prolonged corticosteroid exposure.

 

Healthcare Costs Support Premium Treatment in Severe Patients

Multiple recurrences generate materially higher medical costs than controlled disease. A U.S. claims analysis found average healthcare spending of USD 2,728 per patient per month among patients with multiple recurrences, compared with USD 1,568 among patients without recurrence. Hospitalization rates were 2.22 times higher in the multiple-recurrence group.

Hospitalization during a pericarditis episode averaged approximately USD 30,063. Repeated emergency visits, imaging, specialist consultations, inpatient care, and corticosteroid-related complications can exceed the cost of conventional medicines by a wide margin.

Manufacturers can negotiate coverage around avoided healthcare utilization rather than symptom control alone. Payers will still compare the cost of targeted therapy against recurrences prevented, hospital use, treatment duration, discontinuation rates, and lower-cost alternatives.

Productivity losses add to the economic burden. Patients with repeated recurrences report substantial impairment in work and normal daily activity. Employers and commercial insurers may assign more value to sustained disease control when a working-age patient faces recurrent absence, emergency care, and prolonged treatment.

The reimbursement case is strongest for patients with repeated hospital use, clear inflammatory activity, documented failure of conventional therapy, and a high probability of further recurrence. Broader use in first-recurrence patients will require evidence that earlier intervention reduces long-term utilization enough to justify premium pricing.

 

Specialty-Pharmacy Execution Shapes Commercial Performance

ARCALYST is distributed through a select specialty-pharmacy network rather than conventional retail channels. These pharmacies manage prescription intake, authorization support, delivery, inventory, patient communication, and payer collection.

The model gives Kiniksa better visibility into treatment starts and persistence, but it also concentrates operational risk. Delayed approvals, shipment problems, incomplete documentation, affordability concerns, or poor follow-up can interrupt therapy and reduce revenue. Distribution and reimbursement support therefore form part of the product’s competitive position.

Kiniksa reports generally favourable U.S. payer coverage, although insurers retain control over eligibility criteria, prior authorization, patient cost obligations, and pricing concessions. New therapies could give payers more leverage to negotiate lower net prices or require stricter treatment sequencing.

The company’s gross-to-net adjustment was 8.4% in 2025, down from 9.8% in 2024. The figure indicates the scale of rebates, discounts, and other deductions from gross sales, although it does not represent product margin. Kiniksa also shares ARCALYST profits and certain proceeds with Regeneron after defined manufacturing and commercialization costs, reducing the share of reported revenue retained by Kiniksa.

Reported sales therefore need to be assessed alongside net pricing, treatment duration, patient retention, payer concessions, and partnership economics.

 

Oral Pipeline Assets Could Reshape Treatment Sequencing

Pipeline investment is shifting toward oral therapies and less frequent administration. Developers are targeting lower treatment burden, easier access, and use after patients discontinue IL-1-blocking therapy.

Cardiol Therapeutics is developing oral CardiolRx in the Phase III MAVERIC programme. The trial reached 75% enrollment in April 2026 and is designed to include approximately 110 patients across as many as 25 centres. The programme evaluates whether the therapy can prevent recurrence after withdrawal of IL-1 treatment.

An approved oral option could compete on convenience, patient preference, earlier use, and payer economics. Its commercial position will depend on durability of recurrence prevention, label breadth, safety, pricing, and whether physicians use it instead of biologic treatment or after biologic withdrawal.

Cardiol completed a USD 11.4 million financing in October 2025 and extended its cash runway into the third quarter of 2027. The financing supports late-stage development and a planned U.S. regulatory submission, confirming that the recurrent-pericarditis niche can support meaningful investment despite its limited patient count.

Lilly added another oral programme through its acquisition of Ventyx Biosciences in March 2026. Ventyx had initiated a Phase II recurrent-pericarditis programme for VTX2735, an oral NLRP3 inhibitor. Lilly paid approximately USD 1.1 billion net of acquired cash for the broader Ventyx portfolio, so the transaction value cannot be attributed solely to pericarditis.

Lilly brings greater development capacity, regulatory experience, payer leverage, and commercial reach. A successful oral therapy backed by a large pharmaceutical company could pressure ARCALYST pricing and weaken the advantage created by Kiniksa’s existing field force and specialty-pharmacy network.

 

Kiniksa Is Defending the Franchise Through Longer Dosing Intervals

Kiniksa is developing KPL-387 as a potential monthly subcutaneous treatment for recurrent pericarditis. Data from the dose-focusing portion of its Phase II/III programme are expected in the second half of 2026, with the pivotal portion expected to begin by year-end.

Monthly administration would reduce treatment frequency compared with weekly ARCALYST use and could support patient retention if oral competitors enter the market. The company is also developing KPL-1161 with the objective of quarterly administration, although the asset remains at an earlier stage.

These programmes give Kiniksa a route to compete on convenience before external challengers reach commercialization. They may also support franchise continuity beyond the expiration of ARCALYST’s U.S. orphan exclusivity on March 18, 2028. Kiniksa reports method-of-use patent protection extending to 2038, but differentiated therapies with separate routes, mechanisms, or labels can still compete.

 

North America Leads, While Europe and Asia-Pacific Remain Less Certain

The United States is the only geography with a clearly identified recurrent-pericarditis patient pool, an approved targeted therapy, established specialty-pharmacy distribution, public product revenue, and a broad prescriber base. High specialist concentration, insurance coverage for premium medicines, and active clinical development support continued U.S. leadership.

Europe has a measurable patient base but no comparable branded commercial pathway. The European marketing application for rilonacept in recurrent idiopathic pericarditis was withdrawn in February 2025. A renewed application would need to address regulatory requirements, paediatric evidence, documentation issues, country-level reimbursement, and health-economic thresholds. U.S. revenue trends cannot be applied directly to Europe.

Huadong Medicine holds development and commercialization rights for ARCALYST across a broad Asia-Pacific territory that includes China, India, Southeast Asia, and Australia. A USD 20 million regulatory milestone provides evidence of regional investment, but public data on recurrent-pericarditis patient counts, reimbursement, and indication-level revenue remain limited.

Premium uptake in Asia-Pacific will depend on diagnosis rates, specialist concentration, local approval, affordability, insurance coverage, and competition from inexpensive conventional medicines. Markets with stronger private insurance and established rare-disease reimbursement are likely to develop earlier than those dominated by out-of-pocket payment.

 

Competitive Outlook

Kiniksa leads the current branded market through FDA approval, an established prescriber base, long treatment duration, favourable U.S. coverage, patient-support infrastructure, and direct commercial experience. Regeneron remains an important economic partner, while Huadong provides a regional route into Asia-Pacific.

Cardiol Therapeutics is the most advanced external late-stage challenger and could introduce oral competition if the MAVERIC programme succeeds. Lilly’s ownership of Ventyx adds a better-funded oral development programme with the potential to challenge existing treatment sequencing.

Anakinra remains an off-label IL-1 option in specialist practice, but daily administration and the absence of a specific U.S. recurrent-pericarditis approval limit its commercial position. Conventional medicines will retain most prescription volume but provide limited branded revenue growth.

Future share gains will depend on recurrence prevention, treatment duration, administration burden, payer access, and use earlier in the disease course. Clinical efficacy alone will not secure adoption without specialist education, reimbursement support, reliable onboarding, and sustained treatment persistence.

The market will remain concentrated in recurrent disease, where a relatively small patient group can support substantial specialty-pharmaceutical revenue. Near-term growth will come from deeper penetration of the multiple-recurrence population, earlier identification of eligible patients, longer treatment persistence, and international approvals. Successful oral or less frequently administered therapies could redistribute revenue, while payer scrutiny will increase as more alternatives reach late-stage development.

 

Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 3.30 Billion
Revenue Forecast in 2032	USD 5.41 Billion
Overall Growth Rate	CAGR of 6.4% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Billion, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Application, By End User, By Distribution Channel, By Geography
By Treatment Type	Nonsteroidal Anti-Inflammatory Drugs, Colchicine, Corticosteroids, IL-1 Inhibitors, Immunosuppressive Therapies, Intravenous Immunoglobulin, Other Supportive Therapies
By Application	Acute Pericarditis, Recurrent Pericarditis, Chronic Pericarditis, Constrictive Pericarditis, Post-Pericardiotomy Syndrome
By End User	Hospitals, Specialty Cardiology Centers, Ambulatory Care Centers, Specialty Clinics, Homecare Settings
By Distribution Channel	Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising diagnosis of acute and recurrent pericarditis, wider adoption of colchicine-based treatment protocols, growing use of IL-1 inhibitors for recurrent cases, increasing cardiology outpatient care, and better access to specialty pharmacies for advanced therapies
Customization Option	Available upon request